Orion Biotechnology Canada is a drug discovery company targeting earlier undruggable GPCRs. A biotech firm, Peptilogics is into engineering peptide therapeutics by bringing together computation and biology to
New investors Sands Capital and Vivo Capital have jointly led the financing round, which has also seen participation from new investor Dreavent 6. Sofinnova Partners, New York City
The company is a joint venture between WuXi Biologics and WuXi STA and provides end-to-end contract research, development, and manufacturing of bioconjugates, such as ADCs. Under the terms
The new highly selective, fully human monoclonal antibody, abelacimab has been designed to induce effective hemostasis-sparing anticoagulation through Factor XI inhibition. It shows dual inhibitory activity against both
These therapies will be developed using Ryvu’s stimulator of interferon genes (STING) technology. The deal expands Exelixis’ biotherapeutics portfolio by combining its tumour-specific targeting approaches with the Ryvu’s
The latest move follows a strategic multi-year research collaboration of the entities for pre-clinical development of investigational TIL therapies in November last year. Under the expanded collaboration, Turnstone
An investigational anti-amyloid beta (Aβ) protofibril antibody, lecanemab is developed as part of a strategic research alliance between Eisai and BioArctic. It selectively binds to neutralise and eliminate
Mogrify has developed a suite of platform technologies that use a systematic big-data approach for direct cellular reprogramming and to maintain cell identity. Its epiMOGRIFY and MOGRIFY platforms
The intent to acquire Libtayo was announced on 2 June this year. The two companies entered into an immuno-oncology license and collaboration agreement in 2015. As per the terms of
As part of the collaboration, the companies will carry out an observational study in chronic metabolic disease patients as well as those with increased risk of complications like
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.